21世纪经济报道记者季媛媛上海报道 2025年2月,全球GLP-1药物市场迎来一场地震。 一项由美国《JAMA眼科学》期刊发布的研究指出,诺和诺德旗下明星药物Ozempic(司美格鲁肽注射液)及礼来Mounjaro(替尔泊肽)等GLP-1类降糖药物可能导致严重的视力损害,包括视网膜血管损伤、视神经肿胀甚至失明。尽管病例数量较少(研究涉及9名美国患者),但这一发现迅速引发市场恐慌。 而此前...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.